Electromed, Inc.

Electromed, Inc.ELMDEarnings & Financial Report

NYSE · Health Care · Electromedical & Electrotherapeutic Apparatus

Electromed, Inc. is a specialized medical device firm developing, manufacturing, and distributing advanced respiratory care products. Its core offerings are high-frequency chest wall oscillation systems that clear airway secretions for patients with cystic fibrosis, COPD and other respiratory conditions, serving U.S. home care and clinical customers.

ELMD Q2 FY2026 Key Financial Metrics

Revenue

$18.9M

Gross Profit

$14.8M

Operating Profit

$3.6M

Net Profit

$2.8M

Gross Margin

78.4%

Operating Margin

19.2%

Net Margin

14.6%

YoY Growth

16.3%

EPS

$0.32

Electromed, Inc. Q2 FY2026 Financial Summary

Electromed, Inc. reported revenue of $18.9M (up 16.3% YoY) for Q2 FY2026, with a net profit of $2.8M (up 40.3% YoY) (14.6% margin). Cost of goods sold was $4.1M, operating expenses totaled $11.2M.

Key Financial Metrics

Total Revenue$18.9M
Net Profit$2.8M
Gross Margin78.4%
Operating Margin19.2%
Report PeriodQ2 FY2026

Revenue Breakdown

Electromed, Inc. Q2 FY2026 revenue of $18.9M breaks down across 2 segments, led by Homecare at $17.3M (91.4% of total).

SegmentRevenue% of Total
Homecare$17.3M91.4%
Other$1.6M8.6%

Electromed, Inc. Revenue by Segment — Quarterly Trend

Electromed, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Homecare and Other) has evolved quarter over quarter.

SegmentQ2 FY2026Q1 FY2026Q4 FY2025Q3 FY2025
Homecare$17.3M$14.9M$14.1M
Other$1.6M$951.0K$1.6M

Electromed, Inc. Annual Revenue by Year

Electromed, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $64.0M).

YearAnnual Revenue
2025$64.0Mvs 2024
2024$54.7Mvs 2023
2023$48.1Mvs 2022
2022$41.7M

Electromed, Inc. Quarterly Revenue & Net Profit History

Electromed, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.

QuarterRevenueRevenue YoYNet ProfitNet Margin
Q2 FY2026$18.9M+16.3%$2.8M14.6%
Q1 FY2026$16.9M+15.1%$2.1M12.6%
Q4 FY2025$17.4M+17.3%$2.2M12.7%
Q3 FY2025$15.7M+13.1%$1.9M12.1%
Q2 FY2025$16.3M+18.7%$2.0M12.1%
Q1 FY2025$14.7M+19.0%$1.5M10.0%
Q4 FY2024$14.8M+9.0%$1.8M12.3%
Q3 FY2024$13.9M+14.9%$1.5M10.8%

Income Statement

Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Revenue$13.9M$14.8M$14.7M$16.3M$15.7M$17.4M$16.9M$18.9M
YoY Growth14.9%9.0%19.0%18.7%13.1%17.3%15.1%16.3%

Balance Sheet

Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Assets$48.9M$52.2M$48.9M$52.3M$52.5M$53.8M$53.6M$54.9M
Liabilities$6.4M$7.7M$7.4M$8.7M$8.5M$10.6M$8.9M$9.5M
Equity$42.5M$44.5M$41.5M$43.6M$43.9M$43.2M$44.7M$45.4M

Cash Flow

Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Operating CF$1.4M$4.5M$2.3M$3.2M$2.1M$3.9M$169000$3.0M